Efficiency of lithium salt of disulphide of glutathione and inosine in treatment of multiple sclerosis in experiment

Abstract

We studied the possibility of pharmacological correction of neurological disorders in guinea pigs and rabbits with the lithium salt of disulphide of glutathione and inosine medication in experimental allergic encephalomyelitis caused by inoculation of the main myelin protein in Freund’s complete adjuvant. The intradermal test with the main protein of myelin was accomplished in all animals to confirm the autoimmune process at 21st day after sensibilization. The lithium salt of disulphide of glutathione and inosine medication was administered intramuscularly every other day at a single dose of 10 mg/kg for 5 weeks. The symptoms of experimental allergic encephalomyelitis were more pronounced in rabbits and to a lesser extent in guinea pigs. The high therapeutic efficacy of lithium salt of disulphide of glutathione and inosine was established according to the severity and incidence of neurological disorders (dysfunction of the pelvic organs, ataxia, tremor, paralysis and paresis of the limbs) and lethality rate. Early (at 5 days after sensibilization) and subsequent therapeutic use of lithium salt of disulphide of glutathione and inosine prevented the development of experimental allergic encephalomyelitis in 75% of laboratory animals, in the rest 25% of the animals the course of experimental allergic encephalomyelitis was comparatively mild. There were no lethal outcomes in study group compared with lethal outcomes in 70% of animals in control group. Experimental evidence of neuroprotective effects of lithium in brain ischemia and in neurodegenerative diseases highlights new opportunities for the use of lithium-containing drugs in clinical neurology. It has been confirmed that the lithium salt of glutathione and inosine disulfide has a moderate immunosuppressive effect, inhibiting the biosynthesis of antibodies and the delayed-type hypersensitivity reaction.

Keywords

multiple sclerosis / experimental allergic encephalomyelitis / demyelination / lithium salt of disulphide of glutathione and inosine / central nervous system / experimental study / pharmacological correction

References

[1] Бисага, Г.Н. Применение мезенхимальных стволовых клеток при атрофии зрительных нервов у больных рассеянным склерозом: пилотное исследование / Г.Н. Бисага [и др.] // Анналы клин. и эксперимент. неврологии. - 2017. - Т. 11, № 2. - С. 26-31.

[2] Богуш, Т.А. Глутоксим как ингибитор фенотипа множествен- ной лекарственной резистентности, ассоциированной с экспрессией Рgp / Т.А. Богуш [и др.] // Антибиотики и химиотерапия. - 2010. - Т. 55, № 5-6. - С. 18-23.

[3] Генес, В.С. Таблицы достоверных различий между группами наблюдений по качественным показателям / В.С. Генес. - М.: Медицина, 1964. - 80 с.

[4] Громова, О.А. Литийсодержащее средство для профилакти- ки и лечения цереброваскулярных заболеваний и способ применения данного средства: патент на изобретение № 2367427 / О.А. Громова [и др.] // Офиц. бюл. Федер. службы по интеллектуал. собственности. - 2009. - № 26. - С. 1-10.

[5] Зангиева, З.К. Содержание микроэлементов в нервной ткани и ишемический инсульт / З.К. Зангиева [и др.] // Журн. не- врологии и психиатрии им. С.С. Корсакова. - 2013. - Т. 113, № 3, вып. 2. - С. 30-36.

[6] Завалишин, И.А. Рассеянный склероз: от представлений о патогенезе к лечению / И.А. Завалишин, З.А. Суслина // Невролог. вестн. - 2010. - Т. XLII, вып. 1. - С. 6-8.

[7] Платонов, А.Е. Статистический анализ в медицине и биологии: задачи, терминология, логика, компьютерные методы / А.Е. Платонов. - М.: РАМН, 2000. - 52 с. ВЕСТНИК РОССИЙСКОЙ ВОЕННО-МЕДИЦИНСКОЙ АКАДЕМИИ 3 (63) - 2018

[8] Хохлов, А.П. Миелинопатии и демиелинизирующие забо- левания / А.П. Хохлов, Ю.Н. Савченко. - М.: Медицина, 1990. - 208 с.

[9] Council of Europe. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. - 1986. - 48 p.

[10] De Sarno, P. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis / P. De Sarno [et al.] // J. Immunol. - 2008. - Vol. 181, N 1. - Р. 338-345.

[11] Dwivedi, T. Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins / T. Dwivedi, H. Zhang // Front. Neurosci. - 2015. - Vol. 8, Art. 457. - P. 1-8.

[12] Guide for the Care and Use of Laboratory Animals. - Washington D.C.: The National Academies Press, 2011. - 220 p.

[13] Haskó, G. Immunomodulatory and neuroprotective effect of inosine / G. Haskó, M.V. Sitkovsky, C. Szabó // Trends Pharmacol. Sci. - 2004. - Vol. 25, № 3. - Р. 152-157.

[14] Ragan, C.I. The dephosphorylation of inositol 1,4-bisphosphate to inositol in liver and brain involves two distinct Li+-ensitive enzymes and proceeds via inositol 4-phosphate / C.I. Ragan [et al.] // Biochem. J. - 1988. - Vol. 249, № 1. - Р. 143-148.

[15] Ransohoff, R.M. Multiple sclerosis - a quiet revolution / R.M. Ransohoff [et al.] // Nat. Rev. Neurology. - 2015. - Vol. 11, № 3. - Р. 134-142.

RIGHTS & PERMISSIONS

Antushevich A.E., Grebenyuk A.N., Apchel V.Y., Katsaluha V.V., Korovin A.E., Tsygan N.V., Klimov A.G., Gavrilyuk B.L.